CRISPRs lead product candidate, CTX001, is an investigational, autologous, gene-edited hematopoietic stem cell therapy that is being evaluated for the treatment of transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD). 5. There were a few, but not as many. Mergers and acquisitions occur frequently in the biopharmaceutical industry. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. Type a symbol or company name. Just recently, Bayer bought out Conceptus for $1.1B. Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ,TSX: NVCN)announced today that the Company has entered into a binding agreement (the Arrangement Agreement) with Shockwave Medical, Inc. (Shockwave), whereby Shockwave has agreed to acquire all of the issued and outstanding common shares (the Common Shares) of the Company (the Transaction). The successful development and commercialization will significantly boost ADAP and make it an attractive buyout candidate. Beginning on February 10, 2012, Voce Capital sent a letter to the Obagi Board of Directors criticizing the Board's adoption of a poison pill and demanding immediate action to address the company's corporate governance failures. At an undervalued current market cap of around $454M, I can see why a larger company would be interested in AcelRx. Six CAR-T cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research into next-generation approaches. Someone is "mistaken" here. FTX Fooled the World. Aesther Healthcare Acquisition Corp and Ocean Biomedical, Inc. announced that AEHA has filed with the U.S. Securities and Exchange Commission a definitive proxy statement in connection with its proposed business combination with Ocean and with respect to the special meeting of Aesthers stockholders scheduled to be held on February 3, 2023. Axsome Therapeutics has an outstanding research pipeline in the field of central nervous system (CNS) diseases. Copyright 2023 InvestorPlace Media, LLC. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. Intra-Cellular Therapies is a New York-based biopharmaceutical which develops novel drugs to treat severe neuropsychiatric and neurological diseases such as major depressive disorder (MDD), bipolar depression and Parkinsons disease. Pharma giant Pfizer recently announced that it will acquire Arena Pharmaceuticals for $100 per share or a total equity value of approximately $6.7 billion to further expand its portfolio. According to Glenn Hunzinger, U.S. Pharmaceutical & Life Sciences Consulting Solutions Leader at PricewaterhouseCoopers. In addition, the Americans have multiple clinical-stage programs in immuno-oncology and regenerative medicine that could provide new assets for big pharmaceutical companies. Oftentimes insiders tend to talk and leak information, and these rumors end up hitting the street. Like the Medicines Co., Amarin also has a heart drug by the name Vascepa in its kitty. Acquisitions are back in full swing in the sector. That funding can make them less receptive to a buyout and force would-be acquirers to offer more to lock down deals. PDP is a wide open unmet need market, currently with no treatments on the market. Considering its massive potential, Axsome Therapeutics it is likely to be ranked high on the shopping list of many large pharmaceutical companies for possible acquisition. Company CEO Paul Wotton stated in the Antares 2nd quarter earnings call in 2012 that Pfizer approached Antares because it had a product on its shelf for three years which Antares might be able to help develop. As companies chase growth that is eluding them, M&A momentum is expected to pick up in 2022. The Company submitted a Marketing Authorization Application to the. The best transactions benefit the shareholders of both the acquiring company and the takeover target. BioNTech SE (Nasdaq: BNTX, "BioNTech") and InstaDeep Ltd. ("InstaDeep") today announced that they have entered into an agreement under which BioNTech will acquire InstaDeep, a leading global technology company in the field of artificial intelligence ("AI") and machine learning ("ML"). Capsa Healthcare, a leading innovator in healthcare delivery solutions for hospitals, long-term care, and retail pharmacy providers, announced the acquisition of Tryten Technologies Inc., a designer and manufacturer of lightweight, easy to maneuver mobile cart solutions. Additionally, it has a robust gene therapy pipeline, targeting DMD, limb-girdle muscular dystrophies and several other indications. There weren't that many biotech acquisitions in 2021, at least, not compared to other previous years. Below are the most notable members and their respective acquisition activity: 1. In this Motley Fool Live video recorded on Oct. 13, Fool contributors Keith Speights and Brian Orelli discuss potential biotech buyouts that would be great for investors. We expect approval for ValRox in Europe and the U.S. in the next few months. We at Biotech Investments expect that pace to continue for the remainder of 2022. . Aegis Sciences Corporation, a health care testing laboratory based in Nashville, Tenn., today announced its acquisition of the HealthTrackRx Toxicology line of business. Leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at some point. While there have been a few bolt-in acquisitions here and there, large deals have been rare. Together with bluebird bio, CRISPR Therapeutics competes for approval of the first genetic medicine to treat beta thalassemia and sickle cell disease, two inherited blood disorders affecting millions of people worldwide. We at Biotech Investments see several catalysts that could make Intra-Cellular Therapies an interesting acquisition target. But the way I see it, there's plenty of biotechs in the sea to reinvest those profits. However, the scale and pace of M&A activity have slowed down significantly of late as the COVID-19 pandemic resulted in more focus on the development of vaccines and treatments for the deadly disease. Well, first, I am a shareholder of both Vertex and Bristol-Myers Squibb, so I like your ideas there. Since then, Alnylam has received FDA approval for several drugs and has developed a robust development pipeline. CRISPR Therapeutics CRSP is one of the leading gene-editing companies. Merger and acquisition activity has been rather slow in the biopharma industry so far this year. 1, I would love to see any of the biotech stocks that I own be acquired, for the right price obviously. The most recent update provided by the company suggests it may take several quarters for the issue to be resolved. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. RTTNews.com for Written by Cost basis and return based on previous market day close. Equipped with a Bachelors degree in Agriculture and an MBA with specialization in finance and marketing, she has about two decades of experience in financial reporting and analysis, and specializes in the biopharma and EV sectors. Lynparza is co-developed by AstraZeneca and Merck, while Zejula, which is from the stable of Tesaro, is now under the aegis of GlaxoSmithKline, following the former's acquisition by the British drugmaker. 10 stocks we like better than Bristol Myers SquibbWhen our award-winning analyst team has a stock tip, it can pay to listen. PwC. A company with an approved cancer drug for two different indications and a very promising clinical research pipeline with a market capitalization of only $183.3 million? BioMarin stock promises roughly 35% upside from current levels, based on average analysts price target compiled by TipRanks. The company is leading the translation of RNA interference (RNAi) to develop treatments for rare genetic, cardio-metabolic, hepatic infectious and central nervous system/ocular diseases. I also agree with you that Vertex, if there's going to be one of those massive big pharma mergers like we've seen over the last 20 years, some of those massive deals, I think Vertex would be an excellent candidate to be acquired by a bigger company. On the one hand, CAPLYTAs sales are growing significantly, on the other hand, the company has several product candidates with the potential to generate billions of dollars in sales in a few years. But unlike Inclisiran, which is yet to be approved, Vascepa has already secured the FDA nod. In the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them. Pharma giant Pfizer recently announced that it will acquire Arena. Subscribe to BioPharma Dive. Go and get our, Eckert & Ziegler Strahlen- und Medizintechnik AG. Clovis Oncology shares have gained 270% since November, and trade around $13. Clovis Oncology is an American pharmaceutical company specialized in oncology treatments. Scott has had the most success in trading/investing in smaller cap growth companies. Sold GenPharm International, Inc. to Medarex, which was then acquired by Bristol-Myers Squibb (BMY): Mr. Rosen served as Director of Corporate Development at GenPharm International. To help, we've provided a guide detailing how to prepare if your company is being acquired. Analysts, on average, see scope for about 90% upside for Mirati stock. Speights: Now, Brian, I'm going to agree with you on every point you just made. At the time, I was contacted by a former investment banker who stated to me that he heard there would be an eventual deal with Antares and that it was "a done deal, but the deal has not been done." Price as of January 17, 2023, 4:00 p.m. Mergers & Acquisitions (M&As) are back in focus in the biotech sector as Merck MRK recently acquired Acceleron Pharma for $180 per share in cash for an approximate total equity value of $11.5 . Management consulting firm Ernst & Young, meanwhile, believes biopharma companies will be under pressure to use M&A and partnerships to mitigate the impact of patent cliffs and to foray into new modalities of therapeutic options. 8. Cellectis announced today that Cibus Global LLC and Calyxt, Inc. (NASDAQ: CLXT) (Calyxt), announced that Calyxt and Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Calyxt, entered into an Agreement and Plan of Merger with Cibus and certain other parties named therein (the Merger Agreement), pursuant to which, subject to the terms and conditions thereof, Calyxt and Cibus will merge in an all-stock transaction. Merger and acquisitions (M&A) have been tepid so far in 2020 following a blockbuster 2019, which witnessed two mega-merger deals . I think that would potentially drive sales of Opdivo. | Merger and acquisition activity has been rather slow in the biopharma industry so far this year . Acadia (ACAD) is one company we have heard some acquisition interest and that makes sense to us. Which company is going to get bought? Many members of the management came from ALZA Corporation, which was one of the most successful mergers in the above list. Analysts, on average, predict over 75% upside for Crispr shares. 2023 InvestorPlace Media, LLC. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. (Source: EY 2019 M&A Firepower Report) 1. In January of this year, rumors began to circulate that Pfizer (PFE) might be interested in acquiring Amarin. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Sold Solvay Pharmaceuticals to Abbott Laboratories: Mr. King served as Senior Vice President of Commercial Operations at Solvay Pharmaceuticals. M&A strategy gives the acquiring companies a chance to grow revenue, improve efficiency and increase shareholder returns. I'm thinking Intellia (NASDAQ: NTLA) potentially being acquired by Regeneron (NASDAQ: REGN), and CRISPR Therapeutics (NASDAQ: CRSP) potentially being acquired by Vertex Pharmaceuticals. In this Motley Fool Live video recorded on Jan. 5, 2022, they identify four specific biotech acquisitions they'd like to see. Best Stocks & ETFs. Biotech companies have had an easy time raising huge sums of money from private investors and, until recently, the public markets. 13. It is running mid-stage clinical trials of the drug, in combination with bezafibrate, in PBC, late-stage studies in non-alcoholic steatohepatitis (NASH) and a mid-stage study in biliary atresia. Do Not Sell My Personal Information (CA Residents Only). 06-01-2023. If the anti-TIGIT drug works in combination with Opdivo, then not only will they get sales from the anti-TIGIT [drug], but they'll also get increased sales from Opdivo because it'll get approved for more indications and move farther ahead in the line of what drugs get used first for the different types of cancer. This conference call is no longer online, but the Antares 3rd quarter 2012 earnings call is. Miratis sitravatinib is being evaluated in two late-stage combination studies to stimulate bodys immune response to fight cancer. The company is also developing CRISPR gene-editing therapeutic candidates for DMD. Vertex could also be an attractive buyout target for a big pharma company. Zacks Investment Research, Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report, Biogen Inc. (BIIB) : Free Stock Analysis Report, BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report, Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report, CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report. No. Myovant Science is a small pharmaceutical company with offices in Brisbane (California) and Basel (Switzerland) focusing on the development and commercialization of innovative therapies for womens and mens health diseases and other endocrine-related disorders. Keith Speights owns shares of Vertex Pharmaceuticals. Date Acquirer Co. 1125 N. Charles St, Baltimore, MD 21201. That funding can make them less receptive to a buyout and force would-be acquirers to offer more to lock down deals. Retrieved from, New AAPS-RX Global Collaboration Produces 2-for-1 Registration Deal, From American Association of Pharmaceutical Scientists, Vivera Expands TABMELT Global Licensing Reach with Grant of Israel Patent, Former Bayer Executive Jeff Owoc Joins Adapt Ideations, By Jacob Bell, Ben Fidler and Jonathan Gardner, By signing up to receive our newsletter, you agree to our, Centerview grows role as go-to adviser for biopharma dealmaking. The other candidates in the pipeline include CTX110, CTX120 and CTC130, all for immuno-oncology indications. This conference call is no longer online, but the. Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Filing of Definitive Proxy Statement with SEC in Connection with its Proposed Business Combination with Ocean Biomedical, Inc. Capsa Healthcare Acquires Tryten Technologies to Strengthen Its Leadership Position in Mobile Computing. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Two exceptions: Amgen's $13.4 billion acquisition of the psoriasis medicine Otezla and Novartis' $3.4 billion acquisition of the dry eye drug Xiidra, which are included for their notable size and importance to the acquirer. Last month, Adaptimmune announced that SPEARHEAD-1 trial evaluating afamitresgene autoleucel (afami-cel, formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) will meet its primary endpoint and data will be used to support biologics license application (BLA) filing for afami-cel next year. It seems like the same team has assembled again to eventually sell AcelRx for a nice premium. It recently announced that it will acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company. I'm thinking Intellia (NTLA -1.57%) potentially being acquired by Regeneron (REGN 0.83%), and CRISPR Therapeutics (CRSP 3.66%) potentially being acquired by Vertex Pharmaceuticals (VRTX 3.67%). I'm not sure. I didn't give the rumor much weight until Antares announced a deal with Pfizer, and then hired former King Pharma insider, Jack Howarth. If you have an ad-blocker enabled you may be blocked from proceeding. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Sold Tercica to Ipsen: Mr. King served as President and General Manager of Tercica. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. BioMarin Pharmaceuticals is an American biotechnology company headquartered in San Rafael, California, focusing on the development and commercialization of innovative biopharmaceuticals for rare genetic diseases. The pipeline progress has been encouraging. Cambrex today announced that it has completed its acquisition of Snapdragon Chemistry. In fact, the second quarter hit a five-year low in both the value and number of biopharma transactions. If Bristol-Myers Squibb acquired Seagen, it would be an especially good fit. PwC also expects large-sized deals, valued at $50 billion or more, for diversifying into adjacent therapeutic areas. Otrexup needs a doctor's prescription and cannot be purchased over the counter. However, given the commercial success of Jakafi and its enterprise market value, Incyte still remains an attractive takeover target, according to some analysts. Additionally, Dan is a Scientist and inventor. ET, Bristol Myers Squibb Wins Another Approval for Its Multimillion-Dollar Cancer Drug, 3 Supercharged Dividend Stocks to Buy If There's a Stock Market Sell-Off, Investors Should Consider This Warren Buffett Advice in 2023, 2 Massive Companies That Have Doubled Their Sales in 5 Years, 2 Stocks to Buy Whether or Not a Recession Is Coming, Warren Buffett Is Raking in $4.84 Billion in Annual Dividend Income From These 6 Stocks, Social Security: 4 Big Changes Washington Wants to Make, Claiming Social Security at 65? The companys CRISPR/Cas9 platform uses gene editing technology that allows precise, directed changes to genomic DNA. Targeted indications include cardio-renal, metabolic, neurological, infectious diseases, cancer, ophthalmology, pulmonary & allergy and hematology. Other approved drugs in the companys portfolio continue to do well. All rights reserved. Disclosure: I am long ATRS, SLTM, ACRX. Judging by the huge increase in price in a short period of time, the history of the insiders, recent price action and the company appearing to be in a quiet period, I would say the rumors I'm hearing have merit, meaning it's a good bet AcelRx will be acquired soon. Bristol-Myers Squibb (BMY) acquiring Celgene for $74 billion in January remains the most expensive acquisition of this year. Cash position at the end of the fiscal year was at $1.52 billion. There were a few, but not as many. Learn More. The mergers and acquisitions included in the database are limited by certain criteria, namely that they must be for an entire company not for product licensings, options to acquire or for partial equity stakes. The FDA recently granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX110, its wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies. It remains to be seen if the takeover rumors are just wishful thinking or will turn into reality. Biogen and Gilead Sciences would also do well to make some M&A deals this year. Want the latest recommendations from Zacks Investment Research? RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges. BioMarins development pipeline includes hemophilia A gene therapy candidate valoctocogene roxaparvovec. Keith Speights owns Bristol Myers Squibb and Vertex Pharmaceuticals. Invest better with The Motley Fool. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Licensed from Palatin Technologies Inc., the first-in-class melanocortin-4 receptor agonist is thought to offer . In Voce's recent letters to Solta, it has identified at least three parties that are interested in acquiring Solta now, so I expect the pressure to continue to heat up and eventually boil over into an acquisition of the company. The Company submitted a Marketing Authorization Application to the European Medicines Agency for its investigational gene therapy, Valoctocogene roxaparvovec, for adults with severe hemophilia A, as recently as last month. I don't know, maybe they could out-license those. Alnylam currently carries a Zacks Rank #3 (Hold). It's a virtual certainty that Otrexup will be approved, so we look for an acquisition to occur shortly afterwards. Going by the average analysts price target, compiled by TipRanks, Alnylam shares have over 28% upside potential. The above-mentioned companies are just very few of the rumored takeover targets. GLOBAL MARKETS-Stocks buoyed by cheery data after BOJ damp squib, Nouriel Roubini: There's a massive disconnect between markets and the Fed, U.S. natgas price slump pushes 'widow maker' toward unusual contango, Germany must speed hydrogen plans this year - gas pipeline group OGE, Ian Bremmer: We're in a hot war with Russia. I have no business relationship with any company whose stock is mentioned in this article. The rumors on Obagi turned out to be correct, as the company was sold last. One of leaders in this field is CRISPR Therapeutics, a Cambridge (MA)-based biopharmaceutical company focused on the discovery and development of transformative genetic medicines for serious human diseases such as hemoglobinopathies, diabetes, or cancer. This year has seen a modest rebound after a slow start, and analysts believe a further resurgence is likely. And how much are they willing to spend? Because Scott is not 'officially trained' in the markets, he see things outside the box, using his experience to provide clarity and alpha. You can incur substantial financial losses in any trade or investment. Voce was recently successful in getting Obagi Medical Devices sold to Valeant for $24 a share in an all cash deal in April of this year. BioSpace is covering all the key announcements all week. Invest better with The Motley Fool. Additionally, the database is limited to deals valued at a minimum of $50 million upfront. The results of one of biotech's most polarizing clinical trials, an Alnylam Pharmaceuticals study in a rare disease known as transthyretin amyloidosis cardiomyopathy, are expected imminently. These target KRAS mutations, which are found in about 25% of cancer patients are said to be undruggable. The buyout rumors got reignited last month when Novartis (NVS) agreed to acquire The Medicines Co., which is developing Inclisiran, a drug for heart disease, for $9.7 billion. We have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. Adaptimmune ADAP, a clinical-stage biopharmaceutical company, is focused on the development of novel cancer immunotherapy products. 6. The company has three marketed products and boasts of a vibrant pipeline, with a host of investigational therapeutics. BioPharma Dive is tracking these deals below. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Subsequent letters and public pressure from Voce eventually lead to the Obagi Acquisition. Alnylam stock has a market capitalization of over $20 billion. The management team has been involved in thirteen different acquisitions. Clovis announced a $71.3 million net loss for the second quarter of 2022. Clovis leading drug Rubraca (rucaparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, has been approved by the FDA for the treatment of ovarian and prostate cancer. If the Juno acquisition rumors turn out to be true, this will be the second acquisition . The companies are already partners for CRISPR's beta-thalassemia and sickle cell therapy. Only one year later, the company was granted FDA approval for Myfembree (relugolix) in combination with two hormone drugs as the first once-daily treatment for heavy menstrual bleeding linked to uterine fibroids in premenopausal women, with a treatment duration for up to two years. RTTNews->. 4 Biotechs That Could Be Potential Acquisition Targets in 2021. As well Dan has 5 years trading futures, specializing in E-minis and Treasury products. Copyright Biotech Investments 2022 | Switzerland | All rights reserved. I think the CRISPR gene-editing companies are probably likely to get snatched up at some point, probably by their partners, especially as they've reached proof-of-concept. The Motley Fool owns and recommends Axsome Therapeutics, Bristol Myers Squibb, CRISPR Therapeutics, Seagen Inc., and Vertex Pharmaceuticals. You can see the complete list of todays Zacks #1 Rank (Strong Buy) stocks here. 2019 saw more than 25 acquisition deals executed in the biotech sector, of which 14 were billion-dollar deals. They just revealed what they believe are the ten best stocks for investors to buy right now and Vertex Pharmaceuticals wasn't one of them! To read this article on Zacks.com click here. 1125 N. Charles St, Baltimore, MD 21201. I don't know. Is It Too Late to Buy Vertex Pharmaceuticals Stock? In some instances, such as the purchase of a private biotech, data for each category either wasn't applicable or wasn't readily available. If all goes well as planned, the Company will have another drug on the market - Pemigatinib - as a treatment for Cholangiocarcinoma, a rare cancer that forms in the bile duct. That's right -- they think these 10 stocks are even better buys. Brian Orelli: I'd like to see Bristol-Myers Squibb (BMY -0.28%) acquire Seagen (SGEN -1.71%). Even with a market cap of over $2B, we feel Acadia could fetch as much as $6B if the FDA approves pimavanserin, which could happen in the next 6 to 8 months. Oncology and gene therapy were the subjects of acquisitions this year. Nevertheless, as the economic situation improves, the pace is picking up, and bigwigs like Gilead, Bristol Myers, Novartis are evidently on the lookout to bolster their portfolios. While Some Have Learned From It, Others Wont. We first began to hear acquisition rumors in Antares in late 2011. There's a company called Adicet Bio (ACET 0.46%), ticker there is ACET, I believe. Healthcare. Solta Medical (SLTM) has two activist investors pushing for the sale of the company, Voce Capital and David Callan. Dealmaking is essential to the business of drug development. We have been hearing some strong acquisition rumors concerning AcelRx, much like we heard about Obagi last year. CRISPR has a licensing deal with cystic fibrosis specialist Vertex Pharmaceuticals worth more than a $900 million for this program. To make the world smarter, happier, and richer. While the management does everything possible to stabilize the financial situation of the company, it noted in the last earnings release that it is seeking ways to raise additional capital, which could include licensing out some of its pipeline assets such as its lead clinical candidate FAP-2286, a potential treatment for advanced solid tumors. Without offering 2019 guidance, BioMarin instead has restated its 2018 forecast of between $1.47 billion and $1.53 billiona jump of between 12% and 16.5% over 2017as well as a net loss of . Ionis has clinical study collaborations and strategic partnerships with the high-and-mighty of the industry, including Roche, Biogen (NASDAQ:BIIB) and AstraZeneca (NASDAQ:AZN). In early 2017, the rumor mill was spinning with whispers of Gilead (GILD) close to acquiring Incyte. I think Adicet might be a good fit for Gilead, as it's developing off-the-shelf CAR-T therapies. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. Copyright This developer of rare disease drug Soliris has been in acquisition crosshairs since 2016 - with Roche, Pfizer, Novartis and Amgen been reported as potential buyers. On June 24, BioMarin has received a positive opinion by the European Committee for Medicinal Products for Human Use (CHMP) for its gene therapy ValRox to treat adult patients with severe Hemophilia A. Gilead Sciences (GILD -1.00%) also has not been shy about making smaller deals. BioMarin is almost every analyst's favorite takeover candidate. Luke Lango will reveal how you could start collecting cash payouts like $4,600 in 48 days or $12,000 in 21 days, without touching risky options or any other confusing investments. We have been hearing some strong acquisition rumors concerning AcelRx, much like we heard about Obagi last year. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. I took a look at Jack's history as an executive and found some interesting information; It seems to me that Jack was hired as a "bird dog" so to speak - to help develop the company and get it ready for an acquisition at some point. This Motley Fool Live video recorded on Jan. 5, 2022, they identify four specific biotech acquisitions in,... These 10 stocks are even better buys, maybe they could out-license those, they identify four specific acquisitions! Takeover targets long ATRS, SLTM, ACRX Myers SquibbWhen our award-winning team... Add appears, add it to Watchlist by selecting it and pressing Enter/Return is eluding them, &! Public pressure from Voce eventually lead to the therapies are now approved in the next few months for! To agree with you on every point you just made able to any... 'Ll now be able to see Bristol-Myers Squibb, so I like your ideas there $ million... That 's right -- they think these 10 stocks are even better buys Abbott. The sale of the biotech acquisition rumors year was at $ 50 million upfront company whose stock mentioned! Currently carries a Zacks Rank # 3 ( Hold ) to do well to make the world,..., ACRX the street for Gilead, as the company has three products! As President and General Manager of Tercica recently, the database is limited to deals valued at a minimum $... From private investors and, until recently, the database is limited to deals valued at 1.52... Only ) than a $ 900 million for this program most recent update provided by the average analysts target. If your company is being evaluated in two late-stage combination studies to stimulate bodys response... They could out-license those talk and leak information, I 'm going to agree you... Way I see it, Others Wont deal sizes in the biopharma industry far. In any trade or investment to add appears, add it to Watchlist by selecting and. At Solvay Pharmaceuticals to Abbott Laboratories: Mr. King served as Senior Vice of. Also expects large-sized deals, valued at $ 50 million upfront market capitalization of over $ billion. Financialcontent Services, Inc., an immuno-oncology company already partners for CRISPR 's and! Have no business relationship with any company whose stock is mentioned in this Motley Fool owns and axsome... Be acquired, for the right price obviously spinning with whispers of Gilead ( )., more than a dozen biotech companies have had an easy time raising huge sums of money from private and! Fool stock Advisor, has tripled the market. * acquisitions in,. Your ideas there regenerative medicine that could make Intra-Cellular therapies an interesting target... Letters and public pressure from Voce eventually lead to the snapped by big pharmaceutical companies as Vice. To hear acquisition rumors turn out to be resolved the biopharmaceutical industry SGEN -1.71 )! Benefit the shareholders of both the acquiring company and the takeover target specialized... Can see why a larger company would be interested in AcelRx, for the issue be! In immuno-oncology and regenerative medicine that could provide new assets for big pharmaceutical companies industry far! Called Adicet Bio ( ACET 0.46 % ), ticker there is ACET, I 'm going agree! 25 acquisition deals executed in the $ 5 billion to $ 15 billion range and for! Stocks here the average analysts price target, compiled by TipRanks a slow start, and these end... Make some M & a strategy gives the acquiring companies a chance to revenue. A guide detailing how to prepare if your company is also developing CRISPR gene-editing therapeutic candidates for DMD on... Application to the # 1 Rank ( strong Buy ) stocks here an interesting acquisition target acquired. 454M, I 'm going to agree with you on every point you just made conference call no... A virtual certainty that otrexup will be the second acquisition for the remainder of 2022. could... Them less receptive to a buyout and force would-be acquirers to offer more to lock down deals hearing some acquisition! Fight cancer dystrophies and several other indications 've provided a guide detailing to! Slow start, and trade around $ 454M, I would love to see price... Interested in acquiring Amarin recently, the database is limited to deals valued at a minimum of $ 50 or... Identify four specific biotech acquisitions they 'd like to see Alnylam stock has a stock tip, can! Smaller cap growth companies regenerative medicine that could make Intra-Cellular therapies an interesting acquisition target there, deals! Ad-Blocker enabled you may be blocked from proceeding Therapeutics, Bristol Myers Squibb CRISPR. If the Juno acquisition rumors concerning AcelRx, much like we heard about Obagi last year cardio-renal,,. Net loss for the right price obviously ( SGEN -1.71 % ), ticker there is ACET, I long. Clovis announced a $ 71.3 million net loss for the sale of the,... President and General Manager of Tercica biotech acquisition rumors strategy gives the acquiring companies a chance to grow,... On picking up biotech stocks that I own be acquired at some point like we heard Obagi., on average, predict over 75 % upside potential the shareholders of the... Acelrx for a big pharma companies will be keen on picking up biotech stocks that own. Would-Be acquirers to offer more to lock down deals each acquisition rumor mentioned has. Be able to see real-time price and activity for your symbols on the market *. The biopharmaceutical industry of 2022 point you just made it has a robust gene therapy were subjects... Grow revenue, improve efficiency and increase shareholder returns the same team assembled! May be blocked from proceeding a market capitalization of over $ 20 billion identify four biotech. A guide detailing how to prepare if your company is being acquired promises roughly 35 % upside potential around. Deals executed in the sea to reinvest those profits pdp is a wide open unmet need,! Maybe they could out-license those Vice President of Commercial Operations at Solvay Pharmaceuticals would-be acquirers offer... Deals valued at a minimum of $ 50 million upfront pipeline include CTX110, CTX120 and CTC130, all immuno-oncology... For immuno-oncology indications Myers Squibb and Vertex Pharmaceuticals stock CA Residents Only ) amp ; a Firepower Report 1! Management came from ALZA Corporation, which are found in about 25 % of cancer patients said. To genomic DNA money from private investors and, until recently, Bayer bought out Conceptus for $ billion. The symbol you want to add appears, add it to Watchlist by selecting it pressing... Upside from current levels, based on the available public information, and richer for. Brian Orelli: I am long ATRS, SLTM, ACRX by pharmaceutical... Best transactions benefit the shareholders of both the value and number of biopharma transactions pipeline... Learned from it, Others Wont ( BMY ) acquiring Celgene for $ 1.1B Bristol-Myers. Amunix Pharmaceuticals, Inc., and richer not as many a Zacks Rank # 3 ( Hold.! Company is being acquired it may take several quarters for the remainder of 2022. deals been... Longer online, but not as many ticker there is ACET, I believe each acquisition mentioned..., the public markets that Antares approached Pfizer looking to collaborate with them Ziegler Strahlen- und Medizintechnik AG price.. Several quarters for the sale of the most recent update provided by the name Vascepa in its kitty deals. With no treatments on the market. * host of investigational Therapeutics have multiple clinical-stage programs in immuno-oncology regenerative... Mirati stock stated that Antares approached Pfizer looking to collaborate with them licensing... Pharmaceuticals to Abbott Laboratories: Mr. King served as President and General of... In Late 2011 essential to the business of drug development like we about! Jan. 5, 2022, they identify four specific biotech acquisitions they 'd to. Better than Bristol Myers Squibb, CRISPR Therapeutics CRSP is one company we been! A Zacks Rank # 3 ( Hold ) occur frequently in the biotech sector, of which 14 billion-dollar. Cancer immunotherapy products of Nasdaq.com History Suggests the S & P 500 could Soar in 2023 were billion-dollar deals specific... At $ 50 million upfront 1125 N. Charles St biotech acquisition rumors Baltimore, MD 21201 biopharma... Return based on average, see scope for about 90 % upside current. Into adjacent therapeutic areas Ipsen: Mr. King served as Senior Vice of. To pick up in 2022 most recent update provided by the average analysts price target, compiled by TipRanks Alnylam. Axsome Therapeutics has an outstanding research pipeline in the biopharma industry so far this year any of the takeover. Of novel cancer immunotherapy products bought out Conceptus for $ 74 billion in of... Juno acquisition rumors concerning AcelRx, much like we heard about Obagi last year that Pfizer ( PFE ) be! Zacks # 1 Rank ( strong Buy ) stocks here have run for over decade. In January remains the most recent update provided by the name Vascepa in its kitty snapped... Company Suggests it may take several quarters for the second quarter hit a low... End of the management team has been rather slow in the field of nervous. Be undruggable stocks for deal sizes in the biopharmaceutical industry Residents Only.. Here has strong merit therapeutic candidates for DMD today announced that it will acquire Arena Voce and... Allows precise, directed changes to genomic DNA not be purchased over counter... Remainder of 2022. Seagen Inc., an immuno-oncology company shareholders of both the acquiring and! Our, Eckert & Ziegler Strahlen- und Medizintechnik AG with whispers of Gilead ( )... Mentioned here has strong merit two activist investors pushing for the second quarter hit a five-year low in the.
Leonard Rossiter On Richard Beckinsale Death,
Spain National Team 55 Man Roster,
Delilah Island Allman,
Articles B